
Together with @RossFirestone and @szusmani we are happy to share our thoughts on SUCCESSOR-2 clinical trial published few days ago on @TheLancet #mmsm #mezigdomide @MSKCancerCenter @MSK_DeptOfMed thelancet.com/journals/lance…

Physician scientist @MSKCancerCenter via @DOMSinaiNYC @einstein_mstp

Together with @RossFirestone and @szusmani we are happy to share our thoughts on SUCCESSOR-2 clinical trial published few days ago on @TheLancet #mmsm #mezigdomide @MSKCancerCenter @MSK_DeptOfMed thelancet.com/journals/lance…

#Myeloma Paper of the Day: A differentiated T-cell repertoire (CD8+CD45RA+CD62L-CCR7- T effector cells re-expressing CD45RA (TEMRA)) may define a functionally high-risk group (median time to progression of 2.1 years) of smoldering myeloma patients: pubmed.ncbi.nlm.nih.gov/4206…. #mmsm

Myeloma Paper of the Day, August 26th, Suggested by Robert Orlowski (@Myeloma_Doc) @RossFirestone @DrOlaLandgren @szusmani @LesokhinMD oncodaily.com/science/myelom… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MM #Myeloma @CancerWorldmag

#Myeloma Paper of the Day: Immune-MRD status informs tumor-MRD outcome prognostication in myeloma pts on Len maintenance; T cell profiles enriched w/ activated cytotoxic effectors predict early relapse & quiescent/naïve T-cells predicting remission: pubmed.ncbi.nlm.nih.gov/4085…. #mmsm

It was fun to work with @RossFirestone in writing this editorial for @BloodPortfolio #Blood "More than myeloma: the trouble with “normal” plasma cells", on the recent article from @nickbolli @matteoclaudio84 sciencedirect.com/science/ar… @MSKCancerCenter @MSK_DeptOfMed #mmsm

1/ 🚨New research alert! 🚨Our study in @BloodCancerJnl shows that high WEE1 expression is an independent predictor of poor survival in multiple myeloma (MM), with @RossFirestone, @MalinHultcrantz, @LarryNortonMD, @szusmani, and the rest of the @MSKCancerCenter team! 🧵👇

Therapy–mediated BCMA expression loss after belantamab or anti-BCMA chimeric antigen receptor T cells underlies teclistamab failure in RRMM. ow.ly/sarP50SM9ys #lymphoidneoplasia #immunobiologyandimmunotherapy #multiplemyeloma

Thanks to the investigators and to our patients for help with this work! 7/7

We also found that, at times of active disease, low or undetectable levels of soluble BCMA reported on expression loss, offering a noninvasive method to test BCMA expression in clinical practice settings 6/7

This has implications for BCMA-directed therapy sequencing, especially following the results of the DREAMM-7 and DREAMM-8 trials, as belantamab may become more frequently used in earlier lines of treatment 5/7

Interestingly, prolonged exposure to belantamab wasn't necessary for antigen loss, as we observed it after only 2 months of therapy in one case 4/7

BCMA expression loss in MM had not previously been reported after belantamab treatment, which we found to be due to biallelic loss of the BCMA gene, TNFRSF17 3/7

We found that loss of BCMA expression can (rarely) be seen after BCMA CAR T cell or belantamab mafodotin treatment and limits future response to BCMA-directed CAR T cells and bispecifics. It can be detected by IHC before therapy selection 2/7

Our work with @szusmani and @DavidJChungMD at @MSKCancerCenter looking at antigen escape with BCMA-targeting therapies in #MMSM patients is now out in @BloodJournal authors.elsevier.com/a/1jUXn… 1/7

We also can't ignore that remote healthcare utilization is part of the patient experience. Portal messages and phone calls, while not as burdensome as in-person visits, are important signals of patient unease. #rUHI 6/6

Conclusion: We need to do a better job preparing patients for the expected complications of BsAb and CAR T therapies (both major and minor) to avoid unnecessary healthcare interactions and improve QoL, while still keeping patients safe. 5/6